William C. Bertrand Jr. - 28 Aug 2025 Form 4 Insider Report for Adaptimmune Therapeutics PLC (ADAP)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
29 Aug 2025, 18:25:42 UTC
Prior SEC filing
23 Jun 2025
Next SEC filing
18 Jun 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ William Charles Bertrand

Key filing fact

William C. Bertrand Jr. filed Form 4 for Adaptimmune Therapeutics PLC (ADAP) on 29 Aug 2025.

Key facts

  • This page summarizes William C. Bertrand Jr.'s Form 4 filing for Adaptimmune Therapeutics PLC (ADAP).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 29 Aug 2025, 18:25.

Change

  • Previous filing in this sequence was filed on 23 Jun 2025.
  • Current net transaction value: -$2,091.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001291937 Primary reporting owner

Bertrand William C JR

Relationship
Chief Operating Officer
Address
C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVENUE, MILTON PARK, ABINGDON, UNITED KINGDOM
Signature
/s/ William Charles Bertrand
Signature date
29 Aug 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ADAP transaction

Ordinary Shares with a nominal value of GBP0.001 per share

Sale

Transaction value
$2,091
Shares
-207,000
Change %
-17%
Price
$0.0101*
Shares after
986,352
Date
28 Aug 2025
Ownership
Direct
Footnotes
F1, F2, F3, F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The ordinary shares whose sale is reported on this line are represented by American Depositary Shares ("ADS") and are held in the form of ADSs by the Reporting Person. Each ADS represents six ordinary shares of the Issuer.

Footnote F2

The 207,000 ordinary shares reported in Column 4 are represented by 34,500 ADSs.

Footnote F3

The price reported in Column 4 of $0.01005 per ordinary share is derived from the sale price of $0.0603 per ADS divided by six. These ADSs were sold in multiple transactions at a price of $0.0603. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

Footnote F4

The 986,352 ordinary shares reported in Column 5 are held in the form of 164,392 ADSs by the Reporting Person and represent solely those ADSs held by the Reporting Person following this transaction. Additionally, the Reporting Person holds RSU-style options and other options covering an aggregate of 16,108,722 ordinary shares of the Issuer.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .